SCHEMBL6842813

SCHEMBL6842813

Cc1nn2ccccc2c1-c1nc(-c2ccc(NC(=O)OCc3ccccc3)cc2)c(-c2nc[nH]n2)s1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.39
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
KDR P35968 2/20 0.36
FLT3 P36888 2/20 0.36
AURKA O14965 1/20 0.36
FLT1 P17948 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ITGB3 P05106 2/20 0.35
ITGAV P06756 2/20 0.35
CDK7 P50613 1/20 0.35
CCNH P51946 1/20 0.35
JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL952693 0.83 VCP (0.36)
SCHEMBL13256943 0.82 KDR (0.37) ROCK2PTGDR2PDE3BPDE3ATP53
SCHEMBL6842804 0.82 VCP (0.36)
SCHEMBL6842787 0.81 IGF1R (0.39) KDRFLT3NPSR1JAK2
SCHEMBL6842806 0.80 BRD4 (0.40) SMN1; SMN2
SCHEMBL6842805 0.78 KDM5B (0.38) MAPT
SCHEMBL6842803 0.78 BRD4 (0.35) ROCK2TP53MAPTKDRAURKA
SCHEMBL6842801 0.78 VCP (0.33)
SCHEMBL6842683 0.77 VCP (0.40) POLBSMN1; SMN2
SCHEMBL6842795 0.77 MAPK14 (0.35) KDRPOLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 ROCK2 947/4885PTGDR2 3061/4885PDE3B 953/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 ROCK2 294/4885PTGDR2 381/4885PDE3B 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.